Mark S. Humayun

Dr. Mark Humayun
Known for Co-inventing the Argus Series retina implants

Medical career

Profession Ophthalmologist, Engineer, Scientist and Inventor
Institutions USC Eye Institute

Dr. Mark Salman Humayun, M.D., Ph.D. is an Pakistani American ophthalmologist, engineer, scientist and inventor – the only ophthalmologist ever to be elected a member of both U.S. National Academies of Medicine and Engineering.[1][2] He is a university professor with joint appointments at the Keck School of Medicine of USC and the USC Viterbi School of Engineering.[3]

Dr. Humayun was named a recipient of the National Medal of Technology and Innovation in 2015 and received the award from U.S. President Barack Obama in 2016.[4] The award recognizes "those who have made lasting contributions to America’s competitiveness and quality of life and helped strengthen the Nation’s technological workforce.[5]" Dr. Humayun co-invented the Argus Series retina implants, which are manufactured by Second Sight, and are intended to restore sight to the blind.[6] The Argus Series implants were named by Time Magazine among the top 10 inventions of 2013.[7]

He has more than 100 patents and patent applications,[8] and was nominated by R&D Magazine as Innovator of the Year in 2005.[9][10]

Dr. Humayun was named director of the USC Institute of Biomedical Therapeutics (IBT) in 2012,[11] director of the National Science Foundation BioMimetic MicroElectronic Systems Engineering Research Center,[12] and director of the Department of Energy Artificial Retina Project.[13] He was also inaugural director of the USC Eye Institute and interim chair of the USC Department of Ophthalmology.[14]

Education & Career

Born in Pakistan, Dr Humayun received his B.S. from Georgetown University in 1984, his M.D. from Duke University in 1989, and his Ph.D. from the University of North Carolina, Chapel Hill in 1994.[15] He completed his ophthalmology residency at Duke Eye Center and fellowships in both vitreoretinal and retinovascular surgery at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital. He stayed on as faculty at Johns Hopkins where he rose to the rank of associate professor before moving to USC in 2001.

Tenure at USC

Dr. Humayun is a clinician-researcher at the University of Southern California (USC) Eye Institute,[16] and a professor of ophthalmology and biomedical engineering for the Keck School of Medicine of USC and USC Viterbi School of Engineering. He holds the Cornelius J. Pings Chair in Biomedical Sciences. He was named Professor of Ophthalmology, Biomedical Engineering, Cell and Neurobiology in 2001. He served as Interim Chair, Department of Ophthalmology, in 2013. He was named Inaugural Director of the USC Eye Institute in 2013. He was named Director of the USC Sensory Science Institute in 2013.

California Institute of Technology

Dr. Humayun has served as a Visiting Associate in Medical Engineering at the California Institute of Technology since 2014.[17]

Boards of Directors

He serves on the Board of Scientific Counselors for National Space Biomedical Research Institute,[18] the Board of Directors for the American Society of Retina Specialists,[19] and the Board of Directors of Replenish, Inc.[20]

Research

Dr. Humayun’s research projects[21] focus on the treatment of debilitating eye diseases through advanced engineering.

Argus II retinal prosthesis

Dr. Humayun co-invented the Argus II retinal prosthesis,[22] a retinal implant designed to help patients with genetic retinitis pigmentosa.[23][24] More than 30 clinical trial participants in Argus II trial launched in 2007 at sites in the U.S. and Europe. It was approved by the FDA in February 2013.[25] The first USC Eye Institute patient received the implant post-FDA approval in June 2014,[26] and saw light one week following activation of device.

Stem cell research

Dr. Humayun is one of two principal investigators working with USC Eye Institute researchers to study how to replace damaged retinal pigment epithelial (RPE) cells with stem cells to restore sight,[27] a potential cure for age-related macular degeneration, the leading cause of permanent impairment of reading and fine or close-up vision among people aged 65 years and older.[28] This research is funded by a grant from California Institute for Regenerative Medicine.

Personal life

Dr. Humayun saw his own grandmother lose her vision while in medical school, which motivated him to switch his medical specialty to ophthalmology and specifically innovative research.[29]

Dr. Humayun's paternal grandfather was Dr. Ilahi Buksh, who was personal physician of Muhammad Ali Jinnah the founder of Pakistan.

References

  1. ↑ Lewit, Meghan (23 October 2009). "Humayun Elected to Institute of Medicine". Keck School of Medicine of USC. Retrieved 5 February 2016.
  2. ↑ "Keck School Faculty Honored by National Academy of Engineering". Keck School of Medicine of USC. 16 February 2011. Retrieved 5 February 2016.
  3. ↑ "Biomed Miracle Workers". USC Trojan Family. Retrieved 5 February 2016.
  4. ↑ http://nationalmedals.org/laureates/mark-s-humayan
  5. ↑ "President Obama to Honor Nation's Leading Scientists and Innovators". The White House (whitehouse.gov). 22 December 2015. Retrieved 5 February 2016.
  6. ↑ "Humayun named first director of USC Eye Institute". Keck Medicine of USC. 14 November 2013. Retrieved 5 February 2016.
  7. ↑ "The 25 Best Inventions of the Year 2013". TIME Magazine. 13 November 2013. Retrieved 5 February 2016.
  8. ↑ "Patents by Inventor Mark Humayun". JUSTIA Patents. Retrieved 5 February 2016.
  9. ↑ "USC researcher Mark Humayun wins 2005 R&D Innovator of the Year Award". USC Bioelectronics Research Lab. 20 October 2005. Retrieved 5 February 2016.
  10. ↑ Derra, Skip (12 August 2005). "Bringing Sight to the Blind". R&D Magazine. Retrieved 5 February 2016.
  11. ↑ "Biomed Miracle Workers". USC Trojan Family. Retrieved 5 February 2016.
  12. ↑ "An Engineering Research Center for Biomimetic Microelectronic Systems". National Science Foundation. 24 September 2003. Retrieved 5 February 2016.
  13. ↑ "Overview of the Artificial Retina Project". Artificial Retina Project. Retrieved 5 February 2016.
  14. ↑ "Humayun named first director of USC Eye Institute". Keck Medicine of USC. 14 November 2013. Retrieved 5 February 2016.
  15. ↑ "Mark S. Humayun, MD, PhD". Keck Medicine of USC. Retrieved 5 February 2016.
  16. ↑ "About USC Eye Institute". USC Eye Institute. Retrieved 5 February 2016.
  17. ↑ "Update on Argus II Retinal Prosthesis Study". Caltech Division of Engineering & Applied Science. 13 March 2014. Retrieved 5 February 2016.
  18. ↑ "Mark S. Humayun". USC Press Room. Retrieved 5 February 2016.
  19. ↑ "ASRS Board of Directors". American Society of Retina Specialists (ASRS). Retrieved 5 February 2016.
  20. ↑ "Leadership Team". Replenish, Inc. Retrieved 5 February 2016.
  21. ↑ "Mark S. Humayun". Keck Medicine of USC. Retrieved 6 February 2016.
  22. ↑ "Argus II Retinal Prosthesis System - H110002". U.S. Food and Drug Administration. 13 February 2013. Retrieved 6 February 2016.
  23. ↑ "Seeing is Believing: USC Eye Institute's retinal prosthesis gives blind woman the gift of sight". YouTube. 29 August 2014. Retrieved 6 February 2016.
  24. ↑ Gross, Rachel (31 August 2014). "A Bionic Eye That Restores Sight". The Atlantic. Retrieved 6 February 2016.
  25. ↑ "Argus II Retinal Prosthesis System - H110002". U.S. Food and Drug Administration. 13 February 2013. Retrieved 6 February 2016.
  26. ↑ "USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States". Keck Medicine of USC. 27 August 2014. Retrieved 6 February 2016.
  27. ↑ Lytal, Cristy (3 July 2014). "Mark Humayun and David Hinton look to stem cells to bring sight to the blind". USC Stem Cell. Retrieved 6 February 2016.
  28. ↑ "Common Eye Disorders". Centers for Disease Control and Prevention. Retrieved 6 February 2016.
  29. ↑ Gross, Rachel (31 August 2014). "A Bionic Eye That Restores Sight". The Atlantic. Retrieved 6 February 2016.
This article is issued from Wikipedia - version of the 11/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.